Products
Riltovetbart Biosimilar Monoclonal Antibody (Canine IL-31) for Research
Cat No.: GMP-Bios-INN-1371
Anti-IL31 (Canine) therapeutic antibody (Pre-made Riltovetbart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Riltovetbart (development code ZTS-00008183) is a caninized monoclonal antibody targeting canine interleukin-31 (IL-31). It is developed by Zoetis for canine lupus and atopic dermatitis. Further development details are under investigation.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1371-1mg | 1mg | 3090 |
| GMP-Bios-INN-1371-10mg | 10mg | |
| GMP-Bios-INN-1371-100mg | 100mg | |
| GMP-Bios-INN-1371-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Riltovetbart biosimilar, Whole mAb, Anti-IL31 (Canine) Antibody: Anti-IL-31 therapeutic antibody |
| INN Name | Riltovetbart |
| Target | IL31 (Canine) |
| Format | Whole mAb |
| Derivation | na |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Unknown |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2022 |
| Year Recommended | 2023 |
| Companies | TBC |
| Conditions Approved | na |
| Conditions Active | Canine Lupus |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
